Literature DB >> 12213855

Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene.

Abbie L Young1, Bora E Baysal, Arjun Deb, William F Young.   

Abstract

Approximately 10% of catecholamine-secreting tumors are malignant, and 10% are familial. These tumors have been associated with several hereditary syndromes, including multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome, neurofibromatosis type 1, and familial paraganglioma. Mutations in succinate dehydrogenase (SDH) subunit genes have been identified in some kindreds with catecholamine-secreting tumors. In 1972 at the Mayo Clinic, a metastatic catecholamine-secreting paraganglioma was diagnosed in a 32-yr-old man. In 1979, 7 yr after the initial surgical treatment, a lytic metastasis to the left femur was found and was treated with local external radiotherapy. Locally metastatic abdominal catecholamine-secreting paragangliomas were diagnosed in the patient's 27-yr-old son. Analyses of the VHL, RET, SDHD, and SDHC genes revealed no mutations. However, a missense point mutation was detected in the SDHB gene: c.725G-->A in exon 7, which alters a conserved arginine at amino acid position 242 to a histidine (R242H). Sequencing of the SDHB gene in the tumors did not reveal any somatic mutations or loss of heterozygosity of the remaining allele. Thirty years after the initial diagnosis, the father is one of the longest living survivors of malignant catecholamine-secreting paraganglioma. Our findings indicate that mutations in SDHB may be associated with metastatic, yet clinically indolent, abdominal paraganglioma in some families.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213855     DOI: 10.1210/jc.2002-020312

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators.

Authors:  Kalman Kovacs; David Bell; Geoffrey W Gardiner; R John Honey; Jeannette Goguen; Fabio Rotondo
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 2.  Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel.

Authors:  Andrew P Wojtovich; C Owen Smith; Cole M Haynes; Keith W Nehrke; Paul S Brookes
Journal:  Biochim Biophys Acta       Date:  2013-01-02

Review 3.  SDH-related pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Kathryn S King; Karel Pacak
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

4.  The malignant potential of a succinate dehydrogenase subunit B germline mutation.

Authors:  C Fuentes; E Menéndez; J Pineda; J P Martínez De Esteban; E Anda; M J Goñi; B Bausch; H P H Neumann
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

5.  Low penetrance of a SDHB mutation in a large Dutch paraganglioma family.

Authors:  Frederik J Hes; Marjan M Weiss; Sanne A Woortman; Noel F de Miranda; Patrick A van Bunderen; Bert A Bonsing; Marcel P M Stokkel; Hans Morreau; Johannes A Romijn; Jeroen C Jansen; Annette H J T Vriends; Jean-Pierre L Bayley; Eleonora P M Corssmit
Journal:  BMC Med Genet       Date:  2010-06-11       Impact factor: 2.103

6.  Familial paragangliomas.

Authors:  Cjm Lips; Egwm Lentjes; Jwm Höppener; Rb van der Luijt; Fl Moll
Journal:  Hered Cancer Clin Pract       Date:  2006-10-15       Impact factor: 2.857

Review 7.  Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.

Authors:  William F Young
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

8.  Management of vagal paragangliomas: review of 17 patients.

Authors:  Ricardo González-Orús Álvarez-Morujo; Miguel Arístegui Ruiz; Carlos Martin Oviedo; Itziar Álvarez Palacios; Bartolomé Scola Yurrita
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-29       Impact factor: 2.503

9.  Malignant extra-adrenal pheochromocytoma caused by an SDHB intronic variation leading to a 54-bp deletion in exon 4.

Authors:  T Ercolino; C Taurino; R Sestini; A V Bacca; M Genuardi; M Mannelli; G P Bernini
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

10.  The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients.

Authors:  Jean-Pierre Bayley; Anneliese E M Grimbergen; Patrick A van Bunderen; Michiel van der Wielen; Henricus P Kunst; Jacques W Lenders; Jeroen C Jansen; Robin P F Dullaart; Peter Devilee; Eleonora P Corssmit; Annette H Vriends; Monique Losekoot; Marjan M Weiss
Journal:  BMC Med Genet       Date:  2009-04-15       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.